<DOC>
	<DOCNO>NCT01707147</DOCNO>
	<brief_summary>The aim study monitor safety efficacy treatment linagliptin Korean patient type 2 diabetes mellitus routine clinical setting .</brief_summary>
	<brief_title>A Non Interventional Study Monitor Safety Effectiveness Trajenta ( Linagliptin , 5 mg , q.d ) Korean Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Study Design : PMS Observational study</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : Patients start Trajenta accordance approve label Korea Patients sign data release consent form Exclusion criterion : Patients previous exposure Trajenta current participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>